Meredith A Collins1, Wei Yan2, Judith S Sebolt-Leopold3, Marina Pasca di Magliano4. 1. Program in Cellular and Molecular Biology, University of Michigan, Ann Arbor, Michigan. 2. Department of Pathology, University of Michigan, Ann Arbor, Michigan; Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan. 3. Department of Radiology, University of Michigan, Ann Arbor, Michigan. 4. Program in Cellular and Molecular Biology, University of Michigan, Ann Arbor, Michigan; Department of Surgery, University of Michigan, Ann Arbor, Michigan; Department of Cell and Developmental Biology, University of Michigan, Ann Arbor, Michigan. Electronic address: marinapa@umich.edu.
Abstract
BACKGROUND & AIMS: Kras signaling via mitogen-activated protein kinase (MAPK) is highly up-regulated in pancreatic cancer cells. We investigated whether MAPK signaling is required for the initiation and maintenance of pancreatic carcinogenesis in mice. METHODS: We studied the formation and maintenance of pancreatic intraepithelial neoplasia (PanINs) in p48Cre; TetO-KrasG12D; Rosa26(rtTa-IRES-EGFP) (iKras*) mice and LSL-KrasG12D mice bred with p48Cre mice (KC). Mice were given oral PD325901, a small-molecule inhibitor of MEK1 and MEK2 (factors in the MAPK signaling pathway), along with injections of cerulein to induce pancreatitis. Other mice were given PD325901 only after PanINs developed. Pancreatic tissues were collected and evaluated using histologic, immunohistochemical, immunofluorescence, and electron microscopy analyses. Acinar cells were isolated from the tissues and the effects of MEK1 and 2 inhibitors were assessed. RESULTS: PD325901 prevented PanIN formation, but not pancreatitis, in iKras* and KC mice. In iKras* or KC mice given PD325901 at 5 weeks after PanINs developed, PanINs regressed and acinar tissue regenerated. The regression occurred through differentiation of the PanIN cells to acini, accompanied by re-expression of the acinar transcription factor Mist1. CONCLUSIONS: In iKras* and KC mice, MAPK signaling is required for the initiation and maintenance of pancreatic cancer precursor lesions. MAPK signaling promotes formation of PanINs by enabling dedifferentiation of acinar cells into duct-like cells that are susceptible to transformation.
BACKGROUND & AIMS:Kras signaling via mitogen-activated protein kinase (MAPK) is highly up-regulated in pancreatic cancer cells. We investigated whether MAPK signaling is required for the initiation and maintenance of pancreatic carcinogenesis in mice. METHODS: We studied the formation and maintenance of pancreatic intraepithelial neoplasia (PanINs) in p48Cre; TetO-KrasG12D; Rosa26(rtTa-IRES-EGFP) (iKras*) mice and LSL-KrasG12Dmice bred with p48Cre mice (KC). Mice were given oral PD325901, a small-molecule inhibitor of MEK1 and MEK2 (factors in the MAPK signaling pathway), along with injections of cerulein to induce pancreatitis. Other mice were given PD325901 only after PanINs developed. Pancreatic tissues were collected and evaluated using histologic, immunohistochemical, immunofluorescence, and electron microscopy analyses. Acinar cells were isolated from the tissues and the effects of MEK1 and 2 inhibitors were assessed. RESULTS:PD325901 prevented PanIN formation, but not pancreatitis, in iKras* and KC mice. In iKras* or KC mice given PD325901 at 5 weeks after PanINs developed, PanINs regressed and acinar tissue regenerated. The regression occurred through differentiation of the PanIN cells to acini, accompanied by re-expression of the acinar transcription factor Mist1. CONCLUSIONS: In iKras* and KC mice, MAPK signaling is required for the initiation and maintenance of pancreatic cancer precursor lesions. MAPK signaling promotes formation of PanINs by enabling dedifferentiation of acinar cells into duct-like cells that are susceptible to transformation.
Authors: Eric A Collisson; Christy L Trejo; Jillian M Silva; Shenda Gu; James E Korkola; Laura M Heiser; Roch-Philippe Charles; Brian A Rabinovich; Byron Hann; David Dankort; Paul T Spellman; Wayne A Phillips; Joe W Gray; Martin McMahon Journal: Cancer Discov Date: 2012-05-24 Impact factor: 39.397
Authors: Janel L Kopp; Guido von Figura; Erin Mayes; Fen-Fen Liu; Claire L Dubois; John P Morris; Fong Cheng Pan; Haruhiko Akiyama; Christopher V E Wright; Kristin Jensen; Matthias Hebrok; Maike Sander Journal: Cancer Cell Date: 2012-11-29 Impact factor: 31.743
Authors: A B Lowenfels; P Maisonneuve; G Cavallini; R W Ammann; P G Lankisch; J R Andersen; E P Dimagno; A Andrén-Sandberg; L Domellöf Journal: N Engl J Med Date: 1993-05-20 Impact factor: 91.245
Authors: Zarir E Karanjawala; Peter B Illei; Raheela Ashfaq; Jeffrey R Infante; Kathleen Murphy; Akhilesh Pandey; Richard Schulick; Jordan Winter; Rajni Sharma; Anirban Maitra; Michael Goggins; Ralph H Hruban Journal: Am J Surg Pathol Date: 2008-02 Impact factor: 6.394
Authors: Stefan Eser; Nina Reiff; Marlena Messer; Barbara Seidler; Kathleen Gottschalk; Melanie Dobler; Maren Hieber; Andreas Arbeiter; Sabine Klein; Bo Kong; Christoph W Michalski; Anna Melissa Schlitter; Irene Esposito; Alexander J Kind; Lena Rad; Angelika E Schnieke; Manuela Baccarini; Dario R Alessi; Roland Rad; Roland M Schmid; Günter Schneider; Dieter Saur Journal: Cancer Cell Date: 2013-02-28 Impact factor: 31.743
Authors: Nathan M Krah; Shuba M Narayanan; Deanne E Yugawa; Julie A Straley; Christopher V E Wright; Raymond J MacDonald; L Charles Murtaugh Journal: Dev Cell Date: 2019-08-15 Impact factor: 12.270
Authors: Chia-Yen C Wu; Eileen S Carpenter; Kenneth K Takeuchi; Christopher J Halbrook; Louise V Peverley; Harold Bien; Jason C Hall; Kathleen E DelGiorno; Debjani Pal; Yan Song; Chanjuan Shi; Richard Z Lin; Howard C Crawford Journal: Gastroenterology Date: 2014-08-27 Impact factor: 22.682